Why is Tatva Chintan falling/rising?

As of 18-Sep, Tatva Chintan Pharma Chem Ltd is currently priced at 1,085.00, reflecting a decrease of 18.9 points or 1.71%. The stock has been underperforming recently, having lost 1.91% over the last two days and touching an intraday low of Rs 1076.3. Despite this decline, the stock has shown a positive performance over the past year, generating a return of 10.83%, which is significantly better than the negative returns of -1.96% from the broader market (BSE500). The company maintains a low debt-to-equity ratio of 0.07, which is a positive indicator, and has seen rising investor participation with a delivery volume increase of 9.17% against the 5-day average.
In the broader market context, Tatva Chintan's short-term performance has been less favorable compared to the benchmark, as it has underperformed its sector by 1.21%. However, over the longer term, the stock has outperformed the Sensex with a year-to-date return of 22.90% compared to the benchmark's 6.24%. While the stock is currently facing downward pressure, its historical performance and low debt levels suggest potential resilience, although recent trends indicate a need for caution among investors.